Want to buy a stock at all time low?
On 1/5/2022 Barclays Boosted the Price Target for AVROBIO, Inc. (AVRO) from Overweight to Overweight and the price target from $6.00 to $22.00.
Now AVRO is $1.34. The next important resistance at $3.80.
AVROBIO is a clinical-stage gene therapy company to treat rare diseases following a single dose worldwide.
AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04.
73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company.
JPMorgan Chase and BlackRock Inc. have...
